JP2016508973A5 - - Google Patents

Download PDF

Info

Publication number
JP2016508973A5
JP2016508973A5 JP2015548495A JP2015548495A JP2016508973A5 JP 2016508973 A5 JP2016508973 A5 JP 2016508973A5 JP 2015548495 A JP2015548495 A JP 2015548495A JP 2015548495 A JP2015548495 A JP 2015548495A JP 2016508973 A5 JP2016508973 A5 JP 2016508973A5
Authority
JP
Japan
Prior art keywords
her2
pharmaceutical
pharmaceutical formulation
preparation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548495A
Other languages
English (en)
Japanese (ja)
Other versions
JP6400595B2 (ja
JP2016508973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/077166 external-priority patent/WO2014096051A1/en
Publication of JP2016508973A publication Critical patent/JP2016508973A/ja
Publication of JP2016508973A5 publication Critical patent/JP2016508973A5/ja
Application granted granted Critical
Publication of JP6400595B2 publication Critical patent/JP6400595B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548495A 2012-12-21 2013-12-18 抗her2抗体製剤 Expired - Fee Related JP6400595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745293P 2012-12-21 2012-12-21
US61/745,293 2012-12-21
PCT/EP2013/077166 WO2014096051A1 (en) 2012-12-21 2013-12-18 Anti her2 antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018165536A Division JP2018199720A (ja) 2012-12-21 2018-09-05 抗her2抗体製剤

Publications (3)

Publication Number Publication Date
JP2016508973A JP2016508973A (ja) 2016-03-24
JP2016508973A5 true JP2016508973A5 (enExample) 2017-01-19
JP6400595B2 JP6400595B2 (ja) 2018-10-03

Family

ID=49779926

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015548495A Expired - Fee Related JP6400595B2 (ja) 2012-12-21 2013-12-18 抗her2抗体製剤
JP2018165536A Pending JP2018199720A (ja) 2012-12-21 2018-09-05 抗her2抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018165536A Pending JP2018199720A (ja) 2012-12-21 2018-09-05 抗her2抗体製剤

Country Status (15)

Country Link
US (2) US20150343058A1 (enExample)
EP (1) EP2934582B1 (enExample)
JP (2) JP6400595B2 (enExample)
AU (1) AU2013360812B2 (enExample)
BR (1) BR112015014853A2 (enExample)
CA (1) CA2895869C (enExample)
DK (1) DK2934582T3 (enExample)
EA (1) EA201391729A1 (enExample)
ES (1) ES2773103T3 (enExample)
IL (1) IL239509A0 (enExample)
MX (2) MX367748B (enExample)
PL (1) PL2934582T3 (enExample)
SG (1) SG11201504897YA (enExample)
WO (1) WO2014096051A1 (enExample)
ZA (1) ZA201504564B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
BR112021001194A2 (pt) * 2018-07-25 2021-04-27 Daiichi Sankyo Company, Limited métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
KR20210142694A (ko) * 2019-03-22 2021-11-25 소마로직, 인크. 생물학적 복합 매트릭스에서 샘플-간 피분석물 변동성 감소
AU2020304649B2 (en) 2019-06-28 2025-09-04 Genentech, Inc. Composition and methods for stabilizing liquid protein formulations
WO2021013689A1 (en) * 2019-07-19 2021-01-28 Ichnos Sciences SA Lyophilized antibody formulation
IL295312A (en) 2020-02-28 2022-10-01 Regeneron Pharma Bispecific antigen binding molecules that bind her2, and methods of use thereof
CN114504642B (zh) * 2020-11-17 2026-03-27 江苏奥赛康生物医药有限公司 一种含抗cldn18.2抗体的液体药物组合物
CN114762727A (zh) * 2021-01-15 2022-07-19 海正生物制药有限公司 一种稳定的帕妥珠单抗的药物组合物
MX2024005772A (es) * 2021-11-12 2024-07-22 Beckman Coulter Inc Novedosa formulación para la tinción de anticuerpos conjugados con polímeros.
WO2023140807A1 (en) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of trastuzumab
WO2023202685A1 (en) * 2022-04-22 2023-10-26 Eirgenix, Inc. Pharmaceutical compositons containing anti-her2 antibody for subcutaneous administration
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
WO2003062375A2 (en) * 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK2390267T3 (da) * 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof

Similar Documents

Publication Publication Date Title
JP2014522843A5 (enExample)
JP2020518599A5 (enExample)
JP2016502504A5 (enExample)
JP2016515511A5 (enExample)
JP2013500947A5 (enExample)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2015534580A5 (enExample)
JP2016515124A5 (enExample)
RU2015144287A (ru) Составы конъюгата антитело против egfr-лекарственное средство
JP2014514346A5 (enExample)
JP2017160208A5 (enExample)
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
JP2019501204A5 (enExample)
JP2016528251A5 (enExample)
SI2691112T1 (en) STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
JP2015534577A5 (enExample)
JP2017510661A5 (enExample)
JP2015526440A5 (enExample)
JP2012046518A5 (enExample)
ES2773103T3 (es) Formulación de anticuerpos anti HER2
CN111356476A (zh) Lag-3抗体药物组合物及其用途
TW201922793A (zh) Pd-1抗體和vegfr抑制劑聯合治療小細胞肺癌的用途
JP2013543505A5 (enExample)
JP2018076350A5 (enExample)
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano